Free Trial

Hologic (HOLX) Stock Forecast & Price Target

Hologic logo
$68.22 +0.31 (+0.46%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$68.27 +0.05 (+0.08%)
As of 10/3/2025 07:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Hologic - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
9
Buy
9

Based on 18 Wall Street analysts who have issued ratings for Hologic in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 9 have given a hold rating, 8 have given a buy rating, and 1 has given a strong buy rating for HOLX.

Consensus Price Target

$79.38
16.37% Upside
According to the 18 analysts' twelve-month price targets for Hologic, the average price target is $79.38. The highest price target for HOLX is $94.00, while the lowest price target for HOLX is $68.00. The average price target represents a forecasted upside of 16.37% from the current price of $68.22.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for HOLX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Hologic and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HOLX Analyst Ratings Over Time

TypeCurrent Forecast
10/5/24 to 10/5/25
1 Month Ago
9/5/24 to 9/5/25
3 Months Ago
7/7/24 to 7/7/25
1 Year Ago
10/6/23 to 10/5/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
8 Buy rating(s)
5 Buy rating(s)
7 Buy rating(s)
Hold
9 Hold rating(s)
8 Hold rating(s)
11 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$79.38$78.00$77.42$87.27
Forecasted Upside16.37% Upside16.84% Upside20.27% Upside8.76% Upside
Consensus RatingModerate BuyModerate BuyHoldModerate Buy

HOLX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HOLX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Hologic Stock vs. The Competition

TypeHologicMedical CompaniesS&P 500
Consensus Rating Score
2.56
2.33
2.51
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside16.37% Upside1,395.17% Upside10.49% Upside
News Sentiment Rating
Positive News

See Recent HOLX News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/27/2025Weiss Ratings
0 of 5 stars
 Reiterated RatingHold (C-)
9/19/2025Argus
4 of 5 stars
David Toung
3 of 5 stars
Boost TargetBuy$80.00 ➝ $90.00+31.83%
9/18/2025Stephens
4 of 5 stars
Mason Carrico
Mason Carrico
1 of 5 stars
Reiterated RatingOverweight$78.00+14.37%
8/6/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSector PerformOutperform$72.00 ➝ $87.00+28.28%
7/31/2025Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Target$75.00+11.53%
7/31/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetEqual Weight$65.00 ➝ $69.00+3.22%
7/31/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetNeutral$65.00 ➝ $70.00+4.19%
7/9/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutralBuy$60.00 ➝ $80.00+23.27%
7/8/2025Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetIn-Line$62.00 ➝ $68.00+5.64%
5/27/2025Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold
5/2/2025Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$90.00 ➝ $71.00+33.45%
2/6/2025Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
2/6/2025William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOutperform
2/6/2025Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperformMarket Perform$80.00 ➝ $75.00+3.02%
12/13/2024Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoveragePeer Perform
12/10/2024BNP Paribas
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
12/10/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageHold$85.00+12.15%
11/5/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetOverweight$92.00 ➝ $94.00+17.79%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 03:26 PM ET.


Should I Buy Hologic Stock? HOLX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, October 4, 2025. Please send any questions or comments about these Hologic pros and cons to contact@marketbeat.com.

Hologic
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Hologic, Inc.:

  • The current stock price is around $66, which is significantly lower than the consensus target price of approximately $79.38, indicating potential for price appreciation.
  • Hologic, Inc. has received multiple upgrades from analysts, including a recent upgrade to "buy" from Citigroup, suggesting positive sentiment and confidence in the company's future performance.
  • The company reported a revenue increase of 1.2% year-over-year, demonstrating resilience and growth in its business operations.
  • Hologic, Inc. has a strong market capitalization of approximately $14.75 billion, which reflects its stability and ability to invest in future growth opportunities.
  • With a debt-to-equity ratio of 0.52, Hologic, Inc. maintains a healthy balance sheet, indicating lower financial risk and the ability to manage its debt effectively.

Hologic
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Hologic, Inc. for these reasons:

  • Despite recent upgrades, Wall Street Zen downgraded Hologic, Inc. from a "buy" to a "hold" rating, which may indicate concerns about the stock's short-term performance.
  • The stock has experienced volatility, with a 12-month high of $84.39 and a low of $51.90, suggesting potential risks associated with price fluctuations.
  • Hologic, Inc. has a relatively high price-to-earnings (P/E) ratio of around 27.52, which may indicate that the stock is overvalued compared to its earnings, potentially deterring value-focused investors.
  • Analysts have mixed ratings, with one Strong Buy, eight Buy, and eight Hold ratings, reflecting uncertainty in the stock's future trajectory.
  • The company operates in a competitive market for medical equipment, which may pose challenges in maintaining market share and profitability against rivals.

HOLX Forecast - Frequently Asked Questions

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Hologic is $79.38, with a high forecast of $94.00 and a low forecast of $68.00.

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last twelve months. There are currently 9 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HOLX shares.

According to analysts, Hologic's stock has a predicted upside of 16.37% based on their 12-month stock forecasts.

Over the previous 90 days, Hologic's stock had 3 upgrades by analysts.

Hologic has been rated by research analysts at Argus, Citigroup, Evercore ISI, Mizuho, Morgan Stanley, Royal Bank Of Canada, Stephens, UBS Group, and Weiss Ratings in the past 90 days.

Analysts like Hologic more than other "medical" companies. The consensus rating for Hologic is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how HOLX compares to other companies.


This page (NASDAQ:HOLX) was last updated on 10/5/2025 by MarketBeat.com Staff
From Our Partners